Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Immunome Inc

Healthcare US IMNM

18.61USD
0.03(0.16%)

Last update at 2026-06-08T20:00:00Z

Day Range

18.3319.04
LowHigh

52 Week Range

4.5030.96
LowHigh

Fundamentals

  • Previous Close 18.58
  • Market Cap876.75M
  • Volume1094630
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-28.27100M
  • Revenue TTM14.02M
  • Revenue Per Share TTM0.71
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-18.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.89600M -24.71100M -17.83700M -10.44400M -7.84500M
Minority interest - - - - -
Net income -37.51300M -24.46900M -17.12000M -10.55000M -7.84500M
Selling general administrative 13.63M 11.09M 4.78M 1.52M 0.87M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.63M 0.76M 0.76M 0.61M 0.52M
Ebit -36.90100M -25.20400M -13.01600M -10.34800M -7.70400M
Ebitda -36.27000M -24.70100M -12.26100M -9.72300M -7.18300M
Depreciation and amortization 0.63M 0.50M 0.76M 0.62M 0.52M
Non operating income net other 0.00500M - - - -
Operating income -36.90100M -25.20400M -12.26100M -10.34800M -7.74300M
Other operating expenses 36.90M 25.20M 12.26M 10.35M 7.74M
Interest expense 0.00500M 0.01000M 0.04M 0.11M 0.14M
Tax provision - - - - -
Interest income - - 0.00100M 0.01000M 0.04M
Net interest income 0.00500M -0.01000M -0.03800M -0.09600M -0.10200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.62M -0.24200M -0.71700M 0.11M 0.04M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 36.90M 25.20M 12.26M 10.35M 7.74M
Cost of revenue - - - - -
Total other income expense net 0.00500M 0.49M -5.57600M -0.09600M -0.10200M
Discontinued operations - - - - -
Net income from continuing ops -36.89600M -24.71100M -17.83700M -10.44400M -7.84500M
Net income applicable to common shares -37.51800M -24.71100M -17.83700M -10.44400M -7.84500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 148.54M 24.05M 57.92M 44.52M 5.06M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.27M 2.33M 7.41M 3.13M 0.58M
Total liab 28.66M 7.39M 9.74M 3.18M 40.69M
Total stockholder equity 119.88M 16.65M 48.19M 41.34M -35.63000M
Deferred long term liab - 0.33M 0.33M - -
Other current liab 7.71M 4.64M 6.65M 1.37M 0.67M
Common stock 0.00400M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00400M 0.00100M 0.00100M 0.00100M 0.00000M
Retained earnings -222.80700M -116.00100M -79.10500M -54.39400M -36.55700M
Other liab - - 0.01M 0.00800M 0.02M
Good will - - - - -
Other assets 0.00000M 0.43M 0.43M 0.10M 0.24M
Cash 98.68M 20.32M 49.23M 39.77M 2.54M
Cash and equivalents - - - - -
Total current liabilities 21.83M 7.33M 9.73M 3.04M 1.67M
Current deferred revenue 10.49M - - - -
Net debt -97.02900M -20.03000M -49.22900M -39.15300M -1.97900M
Short term debt 0.31M 0.29M - 0.48M 0.45M
Short long term debt - - - 0.48M 0.21M
Short long term debt total 1.65M 0.29M - 0.61M 0.56M
Other stockholder equity 342.66M 132.65M 127.29M 95.74M 0.93M
Property plant equipment - 0.68M 0.85M 1.53M 1.70M
Total current assets 144.70M 22.65M 56.64M 42.89M 3.12M
Long term investments - - - - -
Net tangible assets - 16.65M 48.19M 41.34M -35.63000M
Short term investments 39.46M - - - -
Net receivables 0.29M 0.85M 4.31M 0.90M -
Long term debt - - - 0.13M 0.11M
Inventory - -0.84700M -4.31200M - -
Accounts payable 3.31M 2.40M 3.08M 1.19M 0.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.02M - -57.92500M -44.52500M -1.51900M
Additional paid in capital - - - - -
Common stock total equity - 0.00100M - 0.00100M -
Preferred stock total equity - - - - -
Retained earnings total equity - -116.00100M - -54.39400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.10M 0.43M 0.43M 0.10M 0.24M
Deferred long term asset charges - - - - -
Non current assets total 3.84M 1.40M 1.29M 1.63M 1.94M
Capital lease obligations 1.65M 0.29M - 0.00000M 0.24M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.24800M -0.07900M -0.58600M -0.23300M -0.22800M
Change to liabilities -2.82800M 1.78M 0.50M 0.07M 0.15M
Total cashflows from investing activities -0.24800M -0.07900M -0.58600M -0.23300M -0.22800M
Net borrowings 0.49M -0.11300M 0.05M -0.61200M -0.55100M
Total cash from financing activities 0.03M 27.77M 49.94M 10.77M -0.55100M
Change to operating activities 2.92M 1.00M -1.71300M 0.14M -0.24800M
Net income -36.89600M -24.71100M -17.83700M -10.44400M -7.84500M
Change in cash -28.90600M 9.46M 37.22M 0.94M -8.18500M
Begin period cash flow 49.33M 39.87M 2.64M 1.70M 9.89M
End period cash flow 20.42M 49.33M 39.87M 2.64M 1.70M
Total cash from operating activities -28.69000M -18.22600M -12.13400M -9.60000M -7.40600M
Issuance of capital stock 0.00000M 27.23M 55.90M 4.62M 0.00000M
Depreciation 0.63M 0.76M 0.76M 0.61M 0.52M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.03M - 55.87M -0.03500M 0.00000M
Other cashflows from financing activities -0.24800M 0.66M 5.54M 11.42M -0.22800M
Change to netincome 5.33M 2.95M 6.16M 0.02M 0.02M
Capital expenditures 0.25M 0.08M 0.59M 0.23M 0.23M
Change receivables - - - - -
Cash flows other operating 5.28M - -2.41100M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -28.90600M - 37.22M - -
Change in working capital 2.24M 2.78M -1.20900M 0.21M -0.10200M
Stock based compensation 5.33M 3.45M 0.62M 0.01M 0.01M
Other non cash items - 0.00400M -0.00200M 0.00300M 0.00900M
Free cash flow -28.93800M -18.30500M -12.72000M -9.83300M -7.63400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMNM
Immunome Inc		 0.03 0.16% 18.61 - - 87.64 10.26 77.74 -38.9213
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Inc

18702 N. Creek Parkway, Bothell, WA, United States, 98011

Key Executives

Name Title Year Born
Dr. Purnanand Duddu Sarma Ph.D. Pres, CEO & Director 1965
Ms. Corleen M. Roche Chief Financial Officer 1966
Dr. Dennis H. Giesing Ph.D. Chief Devel. Officer 1952
Dr. Scott K. Dessain M.D., Ph.D. Co-founder & Chairman of the Scientific Advisory Board NA
Dr. Matthew K. Robinson Ph.D. Chief Technology Officer NA
Dr. Michael J. Morin Ph.D. Chief Scientist 1955
Ms. Sandra G. Stoneman Esq. Chief Legal Officer, Gen. Counsel & Corp. Sec. 1973
Mr. Robert Lapetina VP of Fin. & Corp. Controller NA
Dr. Clay B. Siegall Ph.D. President, CEO & Chairman 1961
Mr. Max Rosett Interim CFO & Executive VP of Operations 1990

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions